These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Salvage therapy with abacavir and other reverse transcriptase inhibitors for human immunodeficiency-associated encephalopathy. Saavedra-Lozano J; Ramos JT; Sanz F; Navarro ML; de José MI; Martín-Fontelos P; Mellado MJ; Leal JA; Rodriguez C; Luque I; Madison SJ; Irlbeck D; Lanier ER; Ramilo O Pediatr Infect Dis J; 2006 Dec; 25(12):1142-52. PubMed ID: 17133160 [TBL] [Abstract][Full Text] [Related]
46. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027 [TBL] [Abstract][Full Text] [Related]
47. Individualising HIV treatment--pharmacogenetics and immunogenetics. Telenti A; Aubert V; Spertini F Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578 [No Abstract] [Full Text] [Related]
48. Screening for abacavir hypersensitivity. Deresinski S AIDS Alert; 2007 Dec; 22(12):140-1. PubMed ID: 18411482 [No Abstract] [Full Text] [Related]
49. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone. Moyle GJ AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622 [No Abstract] [Full Text] [Related]
51. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
52. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. Vilar FJ; Naisbitt DJ; Park BK; Pirmohamed M J HIV Ther; 2003 May; 8(2):42-7. PubMed ID: 12838164 [TBL] [Abstract][Full Text] [Related]